Abstract
The long blood circulation time of albumin has been clinically utilized as a half-life extension technology for improved drug performance. The availability of one free thiol for site-selective chemical conjugation offers an alternative approach to current genetic fusion and association-based products. This special report highlights important factors for successful conjugation that allows the reader to design and evaluate next-generation albumin conjugates. Albumin type, available conjugation chemistries, linker length, animal models and influence of conjugation on albumin pharmacokinetics and drug activity are discussed.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Therapeutic Delivery |
Vol/bind | 8 |
Nummer | 7 |
Sider (fra-til) | 511-519 |
Antal sider | 9 |
ISSN | 2041-5990 |
DOI | |
Status | Udgivet - jul. 2017 |